Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China

China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Innovent Biologics Strikes Partnership Deal With Eli Lilly

China's Innovent clinches new Lilly deal for immunology, cancer drug development

Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat

China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study

China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion

China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda

Innovent's weight-loss drug highlights China challenge for Novo, Lilly